Photo by mufidpwt from unsplash
Patients with resistant hypertension (rHTN) have uncontrolled hypertension despite receiving at least 3 anti-HTN medication classes. The recent PATHWAY-2 Trial demonstrated superior HTN control when spironolactone was added as a… Click to show full abstract
Patients with resistant hypertension (rHTN) have uncontrolled hypertension despite receiving at least 3 anti-HTN medication classes. The recent PATHWAY-2 Trial demonstrated superior HTN control when spironolactone was added as a 4th agent in rHTN. However, the applicability of PATHWAY-2 in
Keywords:
management resistant;
cardiology;
resistant hypertension;
hypertension;
pathway trial
Journal Title: Journal of the American College of Cardiology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!